abstract
PURPOSE OF REVIEW:
Ovarian
cancer is the commonest gynaecological cancer and the fifth leading
cause of cancer death in women worldwide. The majority of patients with
ovarian cancer present at an advanced stage, and up to 70% of those
treated with a curative approach eventually recur and succumb to their
disease. This article examines the management of ovarian cancer over the
years and the role of intraperitoneal chemotherapy in the treatment
algorithm.
RECENT FINDINGS:
The surgical paradigm for
ovarian cancer has changed and the goal is optimal cytoreduction with no
residual disease. Intraperitoneal chemotherapy has been found to be
superior to intravenous treatment alone, and the combination of
cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC) has produced encouraging results with improved
disease-free and overall survivals at acceptable morbidity and mortality
rates.
SUMMARY:
The most important prognostic factor for
ovarian cancer survival is the ability to achieve optimal cytoreduction
with no residual disease. CRS and HIPEC should be considered as an
option for the management of advanced ovarian cancer and further trials
are required to determine its role in both the primary and recurrent
settings.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.